Condition: Healthy Infants · Sponsor: Société des Produits Nestlé (SPN)
This is a randomized, controlled, double-blind, intervention trial of healthy male and female term infants to evaluate the efficacy of the 2 HMOs on beneficially modulating the gut microbiota, gut maturation, gut barrier integrity, immune response, and other developmental outcomes in healthy Chinese infants. The trial consists of 2 randomized formula-fed groups, and a non-randomized breastfed reference group.
This description comes directly from the study's public registry record.
Qiaoji Li · 008613910051543 · qiaoji.li@rd.nestle.com
Joyce Li · 008615810125435 · Joyce.Li@rd.nestle.com
Always discuss trial participation with your own doctor first.
| The International Peace Maternity & Child Health Hospital of China Welfare Institute | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06361719